Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PF-07265803 in LMNA-related dilated cardiomyopathy
NL-OMON55538Phase 3Active, not recruiting
- Sponsor
- Array BioPharma
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF) comparing PF-07265803 with Matching placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk test distance at Week 24. Started May 2019; status: active, not recruiting.
02
Drugs
emprumapimod
03
Conditions
dilated cardiomyopathy (DCM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON55538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55538.